Events & Publications

Alchemab presents at AD/PD, the International Conference on Alzheimer’s and Parkinson’s Diseases

Ralph Minter, Ph.D. presented "Resilience-Associated CD33 Antibody ATLX-1088, A Potent Stimulator of Microglial Phagocytosis" at AD/PD 2024, the International Conference on Alzheimer’s and Parkinson’s Diseases held 6th March 2024. 

Enhancing Antibody Language Models with Structural Information

Alchemab publication and NeurIPS Machine Learning in Structural Biology workshop

Becoming Fluent in Proteins

Source: Cell Systems (November 2023)

Building Representation Learning Models for Antibody Comprehension

Source: Cold Spring Harbour Perspectives in Biology (November 2023)

Alchemab presents at Neuroscience 2023, the Society of Neuroscience annual meeting, held 11-15 November 2023

Michelle Sidor and Iosif Pediaditakis presented the following posters: 'Human-derived CD33 antibody ATLX-1088, a potent stimulator of microglial pharmacology' and 'Netrin-1 and neurodegenerative diseases: Unraveling Therapeutic Avenues'

The Pharmaphorum Podcast

Listen to our CEO, Young Kwon discuss Alchemab's innovative platform and its novel approach to drug discovery on the pharmaphorum podcast.

Alchemab Therapeutics CEO to Present at Wells Fargo 2023 Healthcare Conference

Young at the Wells Fargo 2023 Healthcare Conference

Listen to CEO Young Kwon chat with Wells Fargo analyst Derek Archila at the Wells Fargo 2023 Healthcare Conference. Live webcast scheduled for Sep 7, 2023 at 4:30 pm ET.

The Optimum Perspectives Podcast

Our CEO Young Kwon was delighted to speak with Richard Staines of the Optimum  Perspectives Podcast on how Alchemab is revolutionizing antibody drug discovery with a novel alternative to the classic "choose a target" approach.

Q&A With Alchemab CEO Young Kwon in Drug Target Review

Alchemab profiled in Drug Target Review

Alchemab was delighted to be featured in Drug Target Review in a profile by Izzy Wood. In the article, Izzy and Olivia Cavlan, our Chief Corporate Development and Strategy Officer, discuss the untapped potential of AI in drug target discovery and how Alchemab’s platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting abilities.

Alchemab unveils Alzheimer’s candidate ATLX-1088 targeting CD33 at the Antibody Industrial Symposium 2023

Alchemab's Sandrine Legg, Director of Phenotypic Screening presented data on a potential first-in-class disease-modifying therapeutic for Alzheimer's disease at the Antibody Industrial Symposium in Tours, France on 22 June 2023.

Alchemab unveils Alzheimer’s candidate ATLX-1088 targeting CD33 at the Antibody Industrial Symposium 2023

Alchemab presents new data at CHDI Huntington’s Disease Therapeutics Conference 2023

Alchemab’s Donna Finch, Head of Translational and Clinical Science, presented data on a potential first-in-class disease modifying therapeutic for Huntington’s Disease at the annual CHDI Huntington’s Disease Therapeutics Conference in Dubrovnik, Croatia, on the 26 April 2023.

Alchemab presents new data at CHDI Huntington’s Disease Therapeutics Conference 2023

See the attached presentation to learn more.

Alchemab Therapeutics to present data profiling a novel antibody to Huntingtin Exon 1 at the CHDI Annual Huntington’s Disease Therapeutics Conference

Alchemab Therapeutics and Medicines Discovery Catapult awarded £1.7 million grant from Innovate UKto accelerate development of disease-modifying therapy for Huntington’s Disease

The Chain Podcast

Nature Biotechnology’s academic spinouts 2021

Jane talks at PEGS 2022

Watch Jane's talks at PEGS 2022

Young Kwon and Alchemab profiled in In Vivo

Nature Biotechnology – Alchemab Therapeutics – Cracking the secrets of protective auto-immunity by Michael Eisenstein, 12 September 2022

Alchemab Appoints Young T. Kwon as Chief Executive Officer

AntiBERTa, an Antibody-Specific
Machine Learning Model with Multiple Applications

Jane talks at Genomics England Research Summit

Watch our CSO Jane Osbourn give a talk at the Genomics England Research Summit presenting our incredible work to date!

PEGS Boston 2022 – Parallel Discovery of Therapeutic Antibodies and Novel Targets Using Antibody Repertoires of Resilient Individuals

Watch Jorge Dias, Alchemab Principal Scientist and early member of the team, talk at PEGS Boston on ‘Parallel Discovery of Therapeutic Antibodies and Novel Targets Using Antibody Repertoires of Resilient Individuals’

Genomics England Research Summit – Mining the immune system for protective antibodies

Learn more about B cell immune repertoires from Jane Osbourn, Alchemab CSO & co-founder, presenting at the Genomics England Research Summit

GTC 2022

Catch a replay of Alchemab’s Jin Leem presenting at Nvidia’s GTC 2022 on deciphering the language of antibodies

Alchemab Selected to Access NVIDIA Cambridge-1 Supercomputer to Advance Machine Learning Enabled Antibody Discovery

Alchemab Extends Partnership with Medicines Discovery Catapult

Alchemab Therapeutics Appoints Young T. Kwon, PhD as Chief Financial and Operating Officer

Alchemab Therapeutics Appoints Douglas A. Treco, PhD as Chief Executive Officer

Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses

Alchemab wins Best Emerging Biotech Start-Up at OBN Awards

Alchemab to collaborate with AstraZeneca to use Alchemab’s drug discovery platform for prostate cancer study

Alchemab raises £60 million ($82 million) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics

Alchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease

Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures

Casting a spell: The Killer50 Magic Circle is unveiled

Cambridge companies help develop Covid antibody cocktail

Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium

UK-based Alchemab partners with Amii to accelerate the development of novel therapeutics to cure disease

OBN Awards – Announcement of 2020 Finalists

Agile start-ups partner with academics to find COVID-19 solutions

Illumina unveils first Cambridge cohort for global genomics accelerator

Illumina Accelerator Welcomes First Global Cohort of Genomics Startups

Alchemab: One for the future and another first for Cambridge

Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures

How the U.K. healthcare sector is leveraging its strengths to beat COVID-19